Examining retail purchases of cigarettes and nicotine replacement therapy in Finland by Timberlake, David et al.
Research Paper
Tobacco Induced Diseases 
1
Examining retail purchases of cigarettes and nicotine 
replacement therapy in Finland
David S. Timberlake1,2, Johanna Joensuu1, Terhi Kurko3, Arja H. Rimpelä1,4,5, Jaakko Nevalainen1 
ABSTRACT
INTRODUCTION Finland’s success in achieving the goal of its tobacco endgame largely 
depends on rectifying deficiencies in the delivery of smoking cessation services. 
One such weakness, which has not been documented with empirical data, is 
misuse of nicotine replacement therapy (NRT). This study’s objective was to 
examine purchase patterns of NRT for estimating improper use of the medication. 
The study was based on the assumption that duration of a purchase episode is 
indicative of either proper use or misuse of NRT. 
METHODS The participants (n=728), who purchased at least one NRT product in 
2016 (mostly gum/lozenge), were selected through enrollment in a large customer 
loyalty program in Finland (LoCard). Participants were categorized into one of five 
groups according to their longest purchase episode of NRT, defined by purchases 
made in consecutive, 4-week intervals. 
RESULTS Most participants, who did not adhere to NRT guidelines, either purchased 
the medication for too short (≤4 weeks, 63.5%) or too long (>24 weeks, 13.2%) 
of a purchase episode. Median purchases of NRT in the first month of use were 
one and four in the former and latter, respectively. In contrast to other groups, 
persistent users (>24 weeks) did not curtail purchases of NRT across several 
4-week intervals, suggesting potential for dependence on NRT. 
CONCLUSIONS The observation that most purchase episodes were terminated 
prematurely is consistent with surveys reporting widespread NRT misuse. Given 
uncertainty of greater regulation of NRT sales through legislation, it would be 
prudent for Finnish retailers to promote proper use of the therapy.
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INTRODUCTION
Providing nicotine replacement therapy (NRT) 
to smokers without a doctor’s prescription, via an 
over-the-counter (OTC) purchase, was a significant 
initiative to increase accessibility and use of the 
proven therapy1. Critics argue that easier access to the 
medication reduces the interaction between patient 
and provider, which is critical for a successful quit 
attempt. Others contend that even after prescribing 
medication, physicians seldom provide proper 
cessation counseling2,3. In countries such as Finland, 
pharmacists provided counseling because OTC sales 
of NRT were initially restricted to pharmacies. But, the 
Finnish Parliament approved a law that deregulated the 
NRT market in 2006, allowing retail sales in grocery 
stores, kiosks and gasoline stations4. Prices of NRT 
products, which declined by 15% after deregulation, 
were the least expensive in hypermarkets, followed by 
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supermarkets and pharmacies5. Consequently, sales 
of NRT increased dramatically in Finland6, but not in 
pharmacies7 where consultation occurs on the proper 
use of the medication. 
The initial concern about liberalizing the NRT 
market focused on smokers’ potential for prolonging 
use of the medication beyond the 3-month period set 
by the US Food and Drug Administration (FDA). This 
concern was largely dispelled by studies reporting 
that only 6% of participants purchased and used 
NRT for an extended period of at least six months8,9. 
It is believed that most smokers prolong their use 
of NRT in order to quit or reduce smoking rather 
than satiate an addiction. Consequently, researchers 
advocated that guidelines for duration of NRT use 
be extended beyond the 3-month maximum10,11. A 
more pressing issue relates to the majority of smokers 
who prematurely terminate the use of NRT12. Using 
a longitudinal design, Zhang et al.12 reported that 
smokers who used NRT for less than four weeks had 
a decreased likelihood of achieving abstinence relative 
to the non-NRT users (OR=0.51, 95% CI: 0.38–0.67). 
The ineffectiveness of using NRT for such a brief 
period is concerning because studies, such as the 
ITC Four-Country Survey13, indicate that OTC NRT is 
prematurely terminated among the majority of users. 
Balmford et al.13 reported that 62.9% and 76.3% of 
users of OTC NRT had only used the medication for 
≤4 weeks and ≤8 weeks, respectively. Such studies, 
however, are limited by the use of self-reported data 
that cannot be verified. The alternative of analyzing 
time-series purchases is one means of obviating the 
inaccuracies that occur with survey data. The current 
study used retail data for estimating the percentage 
of NRT users who purchased the medication for too 
short or too long of a purchase episode.
An examination of retail purchases is particularly 
needed in light of Finland’s goal to end the use of 
tobacco by 2030 (i.e. <5% prevalence). The Roadmap 
to a Tobacco–Free Finland specifies several steps in 
treating tobacco dependence14 as part of the larger 
goal of rectifying deficiencies in smoking cessation 
services. As evidence of one such deficiency, Finland 
received the low score of 5/10 points for tobacco 
treatment on the 2016 Tobacco Control Scale15. 
One notable recommendation in the Roadmap is 
to reimburse smokers for medications and remove 
Section 54a from the Medicines Act, the latter 
permitting sales of OTC NRT in retail outlets (e.g. 
grocery stores). The absence of purchase data, which 
predates the deregulation of Finland’s NRT market 
in 2006, precludes assessment of whether purchases 
from retail outlets contribute to greater misuse of 
NRT relative to purchases from pharmacies. The 
current study is neither designed to test effectiveness 
of regulated versus deregulated NRT markets, nor is 
it designed to examine patterns of use and motives for 
purchasing NRT. Instead, this study aims to examine 
the duration of NRT purchase episodes for estimating 
the duration of episodes of NRT use. The goal is to 
verify the extent of NRT misuse13 through estimation 
of purchase episodes that are terminated prematurely. 
The findings could serve as baseline estimates in the 
case of future policy change, and provide retailers 
information that could facilitate efforts to increase 
customers’ adherence to NRT guidelines.
METHODS
Sample selection
Participants of this study were selected through their 
enrollment in a customer loyalty program headed 
by the S Group, a commercial enterprise possessing 
more than 45% of the market share in Finland16. The 
S Group’s large market share minimizes but does 
not negate the possibility that study participants 
could have purchased cigarettes and NRT from other 
sources. Using a database containing customers’ 
email addresses, the S Group contacted members of 
the customer loyalty program in the HOK–Elanto 
retail co-operative in southern Finland. The email 
inquiry sought members’ consent to release basic 
demographic information (age, gender, postal code) 
and purchases made in the year 2016. Release of 
the data, which excluded personal identifiers, was 
intended for research purposes and approved by the 
ethics committee of the University of Helsinki Review 
Board in the humanities and social and behavioral 
sciences. Approximately 5% of members of the loyalty 
program consented to the data release, yielding a 
sample of 13274 customers. Compared to the general 
population in southern Finland, consenting members 
of the loyalty program were predominantly female 
(about 68%), middle-aged (about 46 years old), and 
more educated, which can be attributed to higher 
participation rates16. This is evidenced by the statistic 
indicating that 56% versus 33% of consenting loyalty 
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members and the general population, respectively, 
had a university degree17. Our final analytic sample, 
which excluded S Group personnel, consisted of 
customers who purchased at least one NRT product 
in the year 2016 (n=728).
Measures
The measures were the time, date, and expenditures 
of cigarettes and NRT in the year 2016. Categories of 
NRT consumers were based on the purchase of one or 
more products in consecutive 4-week intervals. The 
categories, which were based on clinical guidelines 
and empirical findings12, correspond to: the early 
terminators (≤4 weeks of use); those who used 
NRT for the minimum period (5–8 weeks); those 
who used NRT for the standard recommended 
period (9–12 weeks); those who extended their 
use of NRT according to revised recommendations 
(13–24 weeks)10; and those who exceeded the 
maximum period of NRT use (>24 weeks). The study 
participants were categorized into one of the five 
mutually exclusive groups according to their longest 
purchase episode, absent a purchase lapse exceeding 
28 days. For example, if a participant had purchased 
NRT on 5 February, 21 February and 16 March, and 
made a subsequent purchase on 9 June, then the 
participant was classified as having purchased NRT 
for 5–8 weeks of use (range: 29–56 days). For those 
participants who had multiple but equal purchase 
episodes, the longest episode in days was selected. 
An interruption in the purchase of NRT exceeding 
one month was used previously in signifying a new 
episode of use9. Our classification scheme did not 
account for those who made bulk purchases of NRT 
for use over a lengthy time period. Furthermore, 
the classification scheme was not based on incident 
purchases, and, thus, does not necessarily represent 
individuals who used NRT for the first time. For 
example, an early terminator who made a purchase in 
January 2016 may have purchased NRT throughout 
the latter part of 2015. 
Based on sales data from the S Group, nicotine 
gum and lozenge constituted 96.9% of the total sales 
volume of all nicotine replacement products. Sales of 
the nicotine patch, which were low and unchanging 
from 2006 (deregulation) through 20136, were 
slightly higher in pharmacies compared to other 
outlets. Given its low overall volume, it is unlikely that 
the nicotine patch was supplemented with copious 
purchases of nicotine gum and lozenge. Data released 
by the S Group included neither the product type 
(e.g. gum, lozenge, patch) nor product characteristics 
such as brand, package size, or dosage in milligrams. 
Expenditures of NRT were available for analysis, but, 
overlapped too much to differentiate product types. 
Thus, we opted not to extrapolate package size from 
expenditure for estimating the supply of NRT for use 
over a designated period. Instead of extrapolating 
package size, we used consecutive purchases over 
4-week intervals as a measure of duration of NRT use, 
which does not imply that the purchase(s) provided 
a sufficient supply of NRT for any given month. 
Although expenditures of NRT were not used in 
extrapolating package sizes, they were summed over 
intervals as a descriptive way of illustrating purchase 
differences among the five groups of NRT consumers.
Data analysis 
The data analyses entailed the use of paired and 
non–paired statistical tests. Non-parametric methods 
were employed due to the skewed distributions of 
purchases and expenditures of NRT and cigarettes. 
The Kruskal–Wallis test on ranks, analogous to a 
one-way ANOVA, was used for comparing purchases 
and expenditures across the five groups of NRT 
consumers. One notable comparison across groups 
was the number of NRT purchases made in the 
first four weeks of a purchase period. The Wilcoxon 
signed rank test was used for testing differences 
within pairs across time periods, by NRT consumer 
group. Purchases in the first four weeks served as 
the baseline for comparisons to purchases made in 
subsequent 4-week intervals. The within-pair tests 
facilitated assessment of whether NRT purchases 
stayed the same or diminished following the first four 
weeks of a purchase episode. 
RESULTS
Characteristics of NRT consumers
The 728 participants made a total of 9300 NRT and 
21601 cigarette purchases in 2016. Most purchases 
of NRT and cigarettes occurred on Friday, making up 
16.2% and 17.4% of total sales, respectively. A higher 
per cent of females versus males (66.9% vs 57.0%) and 
young versus the old (72.9% vs 61.6%) prematurely 
terminated use of NRT. Tests of independence 
Research Paper
Tobacco Induced Diseases 
Tob. Induc. Dis. 2019;17(May):39
https://doi.org/10.18332/tid/108537
4
indicated a statistically significant association between 
NRT consumer group and sex (χ2
(4)
=10.8; p=0.03), 
but not age group (χ2
(8)
=10.5; p=0.3) (Table 1). 
The early terminators, who did not make consecutive 
purchases across 4-week intervals, composed almost 
two-thirds of the entire sample. Of the NRT products, 
15.2% and 11.6% were purchased by the early 
terminators during January 2016 and the other eleven 
months of the year (χ2
(1)
=7.8; p=0.005), respectively, 
suggesting that several early terminators may have 
purchased the medication as part of a New Year’s 
resolution. Among the early terminators (n=462), 
237 had purchased NRT only one time with a median 
expenditure of €6.6 (range: €2 – €30.1). These one-
time purchasers of NRT frequently purchased cigarettes 
as evidenced by a high median number of cigarette 
purchases (31) and cigarette expenditures (€251.8).
The participants who exceeded NRT recommendations 
(>24 weeks, n=96), referred to as persistent users, 
had the fewest cigarette purchases due in part to the 
large per cent (50%) of users who did not make a 
single cigarette purchase in 2016. The persistent 
users had a median purchase gap of NRT that was 
half the value observed in those who bought NRT 
Table 1. Characterizing consumers of nicotine replacement therapy (NRT) by their demographics and purchases 
of NRT and cigarettes in 2016 (n=728 )
All groups Categories of NRT Consumers Test statistic
Early 
termination
Minimum Recommended Extended Exceeded
Sample size 728 462 66 43 61 96
Duration of NRT use 
defining groupa
≤4 
weeks
5–8
weeks
9–12
weeks
13–24
weeks
25–52
weeks
Demographics
Sex (%)
Female 64.8 68.4 51.5 58.1 55.7 65.6
χ2(4)=10.8* Male 35.2 31.6 48.5 41.9 44.3 34.4
Age group (%)
<30b 9.6 11.0 10.6 4.6 9.8 4.2
χ2(8)=10.5 30–49 58.5 58.0 56.1 72.1 49.2 62.5
≥50 years 31.9 31.0 33.3 23.3 41.0 33.3
NRT Purchases
Median purchases/
year
3 1 10 12 23 49 χ2(4)
f=530***
Median purchases/
periodc
2 1 4 6 13 43.5 χ2(4)
f=578***
Purchase gap in 
daysc,d
9 12 12.7 12 8 6 χ2(4)
f=82.5***
NRT Expenditures (€)
Median/year 32.3 13.6 90.1 155.7 233.3 633.0 χ2(4)
f=466*** 
Median/periodc 21.6 9.1 40.6 69.4 145.7 585.1 χ2(4)
f=480*** 
Cigarette Purchases 
& Expenditure
% Purchased in 2016 67.6 71.6 65.1 67.4 67.2 50.0 χ2(4)=17.2** 
Median purchases/
yeare
24 27 34 18 17 11 χ2(4)
f=4.6
Median expenditures 
(€) /yeare
180.4 211.9 224.0 105.5 105.2 91.4 χ2(4)
f=7.2 
a Categories are defined according to purchases made in consecutive 4-week intervals (see Methods), b Includes small number of adolescents (n=18), c Corresponds to the period 
defining each group, d Median was calculated from the distribution of medians of individual participants, excluding those who purchased NRT only one time, e Limited to those 
who made a cigarette purchase in 2016 (n=492), f Kruskal-Wallis test for non-parametric data (one-way ANOVA on ranks). *p<0.05, **p<0.01, ***p<0.0001.
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over the recommended period (6 vs 12; for all groups, 
χ2
(4)
=82.5; p<0.0001). The purchase gaps were 
assessed within periods of consecutive NRT purchases 
(gaps ≤28 days), thus negating the possibility that 
large gaps could be attributed to a later purchase of 
NRT. Almost 5% of the entire sample (n=35) had 
purchased NRT for 13 consecutive 4-week intervals 
in 2016.
Purchases of NRT over time
For the first month of use, purchases of NRT varied 
significantly across the five groups of consumers 
(χ2
(4)
=416.9; p<0.0001), with the median purchase 
ranging from one to four in the early terminators 
and persistent users, respectively (Table 2). Similar 
purchase patterns were observed across the NRT 
consumer groups for the subsequent 4-week 
intervals. In examining within-pair differences, 
we observed statistically significant declines 
in NRT purchases from baseline (i.e. first four 
weeks of a purchase episode) to the subsequent 
4-week intervals in the groups using NRT over 
the minimum, recommended, and extended time 
periods. For example, those who followed minimum 
recommendations had a median of three purchases 
in the first month of use, but only 1.5 purchases 
in weeks five through eight (S=624.5; p<0.001). 
Declines following the first four weeks of purchasing 
NRT were evident for every group with exception 
those who exceeded the guidelines. The latter had a 
median of four purchases in weeks 1–4, weeks 5–8, 
weeks 9–12, and weeks 13–16. By weeks 25–28, a 
significant decline in NRT purchases from baseline 
had been observed (S=760.5; p<0.001). Yet, the 
persistent users’ purchases and expenditures were 
rather stable over the whole period. 
Table 2. A comparison of the quartiles of NRT expenditures and quartiles of number of NRT purchases (in 
parenthesis) across groups of consumers by four-week periods of NRT use
4-Week Period 
of NRT Use
Percentile Categories of NRT Consumers
Early 
termination
≤4 weeks
(n=462 )
Minimum
5–8 weeks
(n=66 )
Recommended
9–12 weeks
(n=43 )
Extended
13–24 weeks
(n=61 )
Exceeded
25–52 weeks
(n=96 )
Weeks 1–4***
25% 5.2€ (1)a 15.2€ (2) 17.7€ (2) 21.7€ (2) 29.8€ (3)
50% 9.1€ (1) 23.3€ (3) 35.4€ (3) 39.2€ (3) 56.0€ (4)
75% 20.1€ (2) 44.7€ (4) 52.0€ (4) 55.3€ (5) 89.7€ (6)
Weeks 5–8***
25% NAb 6.6€ (1) 10.0€ (1) 16.8€ (2) 32.6€ (3)
50% NA 15.8€ (1.5) 19.9€ (2) 30.2€ (3) 55.5€ (4)
75% NA 34.0€ (2) 43.1€ (3) 43.7€ (4) 83.8€ (6.5)
Signed rank test S=624.5** S=206.5** S=157* S=77.5
Weeks 9–12***
25% NA NA 10.0€ (1) 15.0€ (2) 30.0€ (3)
50% NA NA 18.5€ (1) 29.4€ (2) 50.4€ (4)
75% NA NA 30.0€ (2) 43.2€ (4) 85.8€ (6)
Signed rank test S=267** S=349** S=321.5
Weeksc 13–16***
25% NA NA NA 14.9€ (2) 26.0€ (3)
50% NA NA NA 29.9€ (2) 53.7€ (4)
75% NA NA NA 38.6€ (3) 88.5€ (6)
Signed rank test S=316.5** S=175
Weeksc 25–28
25% NA NA NA NA 20.8€ (2)
50% NA NA NA NA 47.4€ (3)
75% NA NA NA NA 72.7€ (5)
Signed rank test S=760.5**
a Each cell represents the quartile 1st (25%), 2nd (50%), or 3rd (75%) of NRT expenditures in euros and quartile of number of NRT purchases (in parenthesis), b Not applicable, 
c The 4-week period was selected because everyone within the respective NRT group had purchased NRT during the specified period. ***p<0.0001 corresponds to a Kruskal–Wallis 
test on ranks of NRT purchases across groups of consumers; **p<0.001 and *p<0.05 correspond to the Wilcoxon signed rank test of NRT purchases across 4-week periods, using the 
first four weeks of a purchase episode as the baseline comparison.
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Concurrent purchases of cigarettes and NRT
The percentage of concurrent purchases of cigarettes 
and NRT in the first and last month of a purchase 
episode, shown in Figure 1, excludes the participants 
who never purchased cigarettes in 2016. Concurrent 
purchases were coded in terms of pairs of consecutive 
purchases of the two products. For example, if a 
customer purchased a cigarette pack on day 5, another 
cigarette pack on day 17, and NRT on day 20, then a 
single concurrent purchase would be coded as having 
occurred within the same week. In this way, the 
coding scheme selected the shortest period between 
a cigarette and NRT purchase.
In their single month of NRT use, the early 
terminators had a lower percentage of concurrent 
purchases relative to other groups, which occurred 
despite frequent purchases of cigarettes throughout 
the year. Concurrent purchases on the same day or 
same week, which occurred frequently for the other 
groups, changed slightly among those who purchased 
NRT over minimum and extended periods. In 
contrast, the decline in the percentage of concurrent 
purchases on the same day/week was more evident 
for those who followed recommendations (75.7% to 
56.8%) and those who exceeded recommendations 
(75.2% to 63.7%). 
Figure 1. Concurrent purchases of cigarettes and NRT in the first month (n=844 purchases) and last month 
(n=286 purchases) of a purchase episode
DISCUSSION
The study’s findings suggest that most consumers 
in Finland are not purchasing NRT over a sufficient 
period of time. Our estimate of those who purchased 
NRT for four weeks or less (63.5%) is remarkably 
similar to use of the medication over the same 
period reported from the ITC Four–Country Survey 
(62.9%)13. The current study also revealed that the 
amount of NRT purchased in the first four weeks 
of a purchase episode was very small in those who 
terminated early relative to those who proceeded to 
purchase NRT over lengthier periods. The correlation 
between amount and duration of NRT purchases 
could be indicative of success or failure of a cessation 
attempt18.
As reported in other studies13,19, the two most 
commonly cited explanations for prematurely 
terminating NRT use, relapse to smoking and 
medication side effects, are legitimate reasons 
according to manufacturers’ guidelines. A third 
explanation may be traced to smokers’ concerns 
about becoming dependent on NRT. Some smokers 
from Finland, who participated in an online forum 
(i.e. STUMPPI quitline)20, advocated the strict and 
Insufficient (≤ 4 weeks)
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Purchases exceeding 28 days
Purchases within 28 days, but 
not same week
Purchases within 7 days, but 
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Same day purchases of 
cigarettes and NRT
Recomm. (9–12 weeks)Minimum (5–8 weeks) Extended (13–24 weeks) Exceeded (>24 weeks)
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limited use of NRT in an effort to avoid nicotine 
dependence. Yet, the same smokers acknowledged 
that such practice could lead to an unsuccessful quit 
attempt. In our study, it is likely that many early 
terminators failed to quit smoking as a function of 
their frequent cigarette purchases and dependence on 
nicotine. A fourth explanation for early termination 
could be traced to improper NRT use arising from 
lack of instruction and guidance. One study reported 
that among US smokers who used nicotine gum, only 
58% read any of the product inserts21. 
Our estimate of the NRT purchases exceeding 24 
weeks (13.2%) was higher than expected. The most 
likely explanation is that the US study, which reported 
6% of participants who purchased NRT for a minimum 
of six months9, estimated incidence of persistent use, 
whereas, our study estimated prevalence of persistent 
use. Some persistent users identified in our study in 
2016 probably used NRT throughout 2015, leading 
to a higher estimate than that reported by Shiffman 
et al.9. Another explanation for our higher estimate is 
the European guideline recommending the extended 
use of NRT22. In contrast, the study conducted by 
Shiffman et al.9 was conducted prior to the US FDA’s 
recommendation to extend duration of NRT use10. It is 
notable that 71.6% versus 50% of the early terminators 
and persistent users, respectively, had purchased 
cigarettes in 2016. While we do not know the smoking 
status of those who did not purchase cigarettes, it is 
likely that most were former smokers who replaced 
their habit with pharmaceutical nicotine. Current 
knowledge suggests that persistent use of NRT is less 
harmful than smoking cigarettes. Unlike other groups 
in our study, the persistent users did not curtail their 
use of NRT for several weeks following initiation of a 
purchase episode. While this is a concern, dependence 
on oral NRT is an uncommon occurrence23.
In lieu of an amendment to the Medicines Act, 
retailers could take a number of actions to increase 
customers’ adherence to NRT guidelines. They 
could, for example, increase customers’ exposure to 
the guidelines through the dissemination of more 
instructional brochures. Another option, which 
is currently being discussed by the S Group, is an 
online database of purchases of customers enrolled 
in the loyalty program. At the moment, consideration 
is being given to tracking grocery purchases for 
improving the health and nutrition of customers. 
If such a database were to be developed, then 
NRT purchases could be readily added along with 
recommendations for increasing customers’ proper 
use of the medication. An online feature would be 
particularly useful because of the high per cent of 
young customers (<30 years old) who use the Internet 
but do not properly use NRT. While any one of these 
retailer initiatives could modify consumer behavior, 
they are not proven as effective interventions.
Limitations
The time-series analysis of retail purchases of 
cigarettes and NRT minimized the measurement 
error that frequently occurs in survey data. Yet, there 
are limitations that need to be acknowledged with 
regard to using purchase data. First, the cigarette and 
NRT purchases could have been used by someone 
other than the purchaser, such as a family member. 
Data indicating more than one smoker per smoking 
household9 suggest the possibility of multiple quit 
attempts within the same household. Consequently, 
single purchasers of NRT within such households 
could have inflated our estimate of NRT purchases 
per customer. The second limitation is that a loyalty 
member may have purchased NRT in an S Group 
market, but purchased cigarettes elsewhere (or vice 
versa); consequently, neither smoking status nor 
prevalence of NRT use could be determined. Third, 
our categorization of NRT consumer groups was based 
on purchase episodes in 2016, not purchase incidents. 
This limitation precluded us from estimating an 
individual’s risk of becoming a persistent user of 
NRT. We could not determine if the longest purchase 
episode of NRT occurred in 2016, or some period 
prior to 2016. Further, we could not determine if an 
individual who purchased NRT in the latter part of 
2016 continued to purchase NRT throughout 2017. 
An additional limitation was the inability to assess 
whether the study’s findings can be generalized from 
the sample of loyalty members who purchased NRT 
to the population of NRT consumers in southern 
Finland. One surrogate measure for purchasing NRT 
is smoking status. Yet, the absence of data on smoking 
status in the sample and population precluded us 
from weighting our estimates according to population 
proportions of smokers and non-smokers. Since the 
highly educated were oversampled in our study, it 
is likely that any such weighting scheme would 
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have yielded a proportion of early terminators of 
NRT that exceeded the proportion reported in the 
current study. Yet, in the absence of a weighting 
scheme, the estimate for early termination of therapy 
was already inflated by the higher percentage of 
female customers (who were oversampled) versus 
male customers who terminated purchases of NRT 
prematurely. In contrast, Balmford et al.13 reported 
that female smokers had greater odds, though non-
significant, than male smokers of completing a course 
of treatment (OR=1.24, 95% CI: 0.95–1.61). 
The absence of product type (e.g. gum, lozenge) 
and product characteristics (e.g. package size) 
precluded an accurate assessment of whether a 
consumer purchased a sufficient amount of NRT to 
cover a 4-week period. The alternative of using more 
detailed data from Nielsen Company’s Homescan 
Consumer Panel was not an option because of the 
insufficient number of participating households 
in Finland (n=5000; pers. comm. Ethan Markovitz, 
Manager, Client Solutions, Nielsen). Even if more 
detailed data were available, such information would 
not have accounted for the variability in daily use of 
oral NRT9. 
CONCLUSIONS
This study supports findings from survey data 
indicating that most users of NRT terminate the 
therapy prematurely. In the latest proposal to end 
tobacco use in Finland by the year 2030, a working 
group commissioned by the Ministry of Social Affairs 
and Health recommended amending the Medicines 
Act for greater monitoring of the distribution 
channels of OTC NRT24. Yet, given the uncertainty 
of any amendment to the Act, it would be prudent 
for retailers to take steps to increase customers’ 
knowledge of proper NRT use and awareness of NRT 
purchases.
REFERENCES
1. Shiffman S, Sweeney CT. Ten years after the Rx-to-
OTC switch of nicotine replacement therapy: what 
have we learned about the benefits and risks of non-
prescription availability? Health Policy. 2008;86(1):17-
26. doi:10.1016/j.healthpol.2007.08.006
2. Shiffman S, Ferguson SG, Hellebusch SJ. Physicians’ 
counseling of patients when prescribing nicotine 
replacement therapy. Addict Behav. 2007;32(4):728-739. 
doi:10.1016/j.addbeh.2006.06.021
3. Solberg LI, Asche SE, Boyle RG, Boucher JL, Pronk 
NP. Frequency of physician-directed assistance for 
smoking cessation in patients receiving cessation 
medications. Arch Intern Med. 2005;165(6):656-660. 
doi:10.1001/archinte.165.6.656
4. Kurko T, Linden K, Vasama M, Pietila K, Airaksinen 
M. Nicotine replacement therapy practices in Finland 
one year after deregulation of the product sales--has 
anything changed from the community pharmacy 
perspective? Health Policy. 2009;91(3):277-285. 
doi:10.1016/j.healthpol.2008.12.013
5. Aalto-Setala, V and A Alaranta. Effect of deregulation 
on the prices of nicotine replacement therapy products 
in Finland. Health Policy. 2008. 86(2-3): p. 355-62. 
doi:10.1016/j.healthpol.2007.11.013
6. Kurko T. Deregulation of Nicotine Replacement Therapy 
Products in Finland: Reason for Pharmaceutical Policy 
Changes and Reflections on Smoking Cessation Practices. 
Finland: University of Helsinki; 2005.
7. National Agency of Medicines and Social Insurance 
Institution. Sales of nicotine replacement therapy 
products. Helsinki, Finland: F.S.o. Medicines; 2007.
8. Shiffman S, Hughes JR, Di Marino ME, Sweeney CT. 
Patterns of over-the-counter nicotine gum use: persistent 
use and concurrent smoking. Addiction. 2003;98(12):1747-
1753. doi:10.1111/j.1360-0443.2003.00575.x
9. Shiffman S, Hughes JR, Pillitteri JL, Burton SL. Persistent 
use of nicotine replacement therapy: an analysis of actual 
purchase patterns in a population based sample. Tob 
Control. 2003;12(3):310-316. doi:10.1136/tc.12.3.310
10. Fucito LM, Bars MP, Forray A, Rojewski AM, Shiffman S, 
Selby P, West R, Foulds J, Toll BA, Writing Committee 
for the SRNT Policy and Treatment Networks. Addressing 
the evidence for FDA nicotine replacement therapy label 
changes: a policy statement of the Association for the 
Treatment of Tobacco use and Dependence and the 
Society for Research on Nicotine and Tobacco. Nicotine 
Tob Res. 2014;16(7):909-914. doi:10.1093/ntr/ntu087
11. Zapawa LM, Hughes JR, Benowitz NL, Rigotti 
NA, Shiffman S. Cautions and warnings on the 
US OTC label for nicotine replacement: what’s a 
doctor to do? Addict Behav. 2011;36(4):327-332. 
doi:10.1016/j.addbeh.2010.12.003
12. Zhang B, Cohen JE, Bondy SJ, Selby P. Duration of 
nicotine replacement therapy use and smoking cessation: 
a population-based longitudinal study. Am J Epidemiol. 
2015;181(7):513-520. doi:10.1093/aje/kwu292
13. Balmford J, Borland R, Hammond D, KM Cummings. 
Adherence to and reasons for premature discontinuation 
from stop-smoking medications: data from the ITC Four-
Country Survey. Nicotine Tob Res. 2011;13(2):94-102. 
doi:10.1093/ntr/ntq215
14. Ministry of Social Affairs and Health. Roadmap to a Tobacco-
Free Finland: Action Plan on Tobacco Control. Helsinki, 
Finland: Ministry of Social Affairs and Health; 2014.
Research Paper
Tobacco Induced Diseases 
Tob. Induc. Dis. 2019;17(May):39
https://doi.org/10.18332/tid/108537
9
15. Joossens L, Raw M. The Tobacco Control Scale 2016 in 
Europe. Belgium, Brussels: A.o.E.C. Leagues; 2017.
16. Nevalainen J, Erkkola M, Saarijarvi H, Nappila T, Fogelholm 
M. Large-scale loyalty card data in health research. Digit 
Health. 2018;4. doi:10.1177/2055207618816898
17. Preliminary and unpublished data from the LoCard data 
collection for 2016-2018, 2019.
18. Raupach T, Brown J, Herbec A, Brose L, West R. A 
systematic review of studies assessing the association 
between adherence to smoking cessation medication 
and treatment success. Addiction. 2014;109(1):35-43. 
doi:10.1111/add.12319
19. Burns EK, Levinson AH. Discontinuation of nicotine 
replacement therapy among smoking-cessation 
attempters. Am J Prev Med. 2008;34(3):212-215. 
doi:10.1016/j.amepre.2007.11.010
20. Kurko T, Linden K, Kolstela M, Pietila K, Airaksinen 
M. Is nicotine replacement therapy overvalued in 
smoking cessation? Analysis of smokers’ and quitters’ 
communication in social media. Health Expect. 
2015;18(6):2962-2977. doi:10.1111/hex.12280
21. Bansal MA, Cummings KM, Hyland A, Giovino GA. 
Stop-smoking medications: who uses them, who 
misuses them, and who is misinformed about them? 
Nicotine Tob Res. 2004;6(Suppl 3):S303-310. 
doi:10.1080/14622200412331320707
22. Royal College of Physicians. Harm reduction in nicotine 
addiction: Helping people who can’t quit. London, 
England: Royal College of Physicians; 2007.
23. Hughes JR, Pillitteri JL, Callas PW, Callahan R, Kenny 
M. Misuse of and dependence on over-the-counter 
nicotine gum in a volunteer sample. Nicotine Tob Res. 
2004;6(1):79-84. doi:10.1080/14622200310001656894
24. Ministry of Social Affairs and Health: Smoke-free Finland 
through better tobacco and nicotine policy. https://stm.
fi/artikkeli/-/asset_publisher/tyoryhma-tupakka-ja-
nikotiinipolitiikkaa-kehittamalla-suomi-savuttomaksi. 
Accessed May 31, 2018.
ACKNOWLEDGEMENTS
The authors thank the S Group for the use of retail purchases from 
members of the customer loyalty program. The primary author thanks 
the Fulbright Finland Foundation for providing salary and other 
resources which made this project possible. We thank three anonymous 
reviewers for their helpful suggestions.
CONFLICTS OF INTEREST
The authors declare that they have no competing interests, financial or
otherwise, related to the current work. T. Kurko is a member of the 
working group appointed by the Finnish Medical Society Duodecim 
and the Finnish Association for General Practice of the Tobacco and 
Nicotine Dependency, Prevention and Treatment Current Care Guideline. 
The rest of the authors have also completed and submitted an ICMJE 
form for disclosure of potential conflicts of interest.
FUNDING
The study was supported by the Finland Fulbright Foundation.
AUTHORS’ CONTRIBUTIONS
D.S.T., J.J. and J.N. formulated the hypothesis and analytical 
methodology. D.S.T. and J.J. coded the data and conducted the 
statistical analyses. T.K. and A.H.R. provided policy insight, guidance on 
clinical recommendations and patterns of N.R.T. use typically observed 
in practice. D.S.T. wrote most of the manuscript and J.J., T.K., A.H.R. and 
J.N. provided critical review and editing.
PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.
